Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03133221 · OUTCOME

Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation · Source last updated 2025-06-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
1 year.

What was measured

The proportion of patients who discontinued the study due to Zydelig-related adverse events.

Groups in this outcome

Oral Zydelig 150 mg BID

Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity. Zydelig: Zydelig given at 150mg continuously in 28-day cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Oral Zydelig 150 mg BID17

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Oral Zydelig 150 mg BID5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        5
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
The proportion of patients who discontinued the study due to Zydelig-related adverse events.
groups
  1. description
    Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity. Zydelig: Zydelig given at 150mg continuously in 28-day cycles
    id
    OG000
    title
    Oral Zydelig 150 mg BID
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
1 year.
title
Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice